Pharmacogenetics of ADHD;Farmakogenetika ADHD

Ceska a Slovenska Psychiatrie

Volumn 106, Issue 4, 2010, Pages 226-229

  Ptáček, Radek ^a   Kuželová, Hana ^a,b   Macek Jr , Milan ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

ADHD; Genetic polymorphism; Pharmacogenetics; Stimulancia

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; SEROTONIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; ATTENTION DEFICIT DISORDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77957002829     PISSN: 12120383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brophy K, Hawi Z, Kirley A, Fitzgerald M, Gill M. Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. Mol Psychiatry 2002; 7 (8): 913-917.
2. Da Silva TL, Pianca TG, Roman T et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attention- deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm 2008; 115 (2): 341-345.
3. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 2005; 15 (1): 95-101.
4. Contini V, Victor MM, Marques FZ, Bertuzzi GP, Salgado CA, Silva KL, Sousa NO, Grevet EH, Belmonte-de-Abreu P, Bau CH. Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD. J Neural Transm 2010; 117 (2): 269-276
5. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010; 33(1): 159-180.
6. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 2010; 24 (2): 99-117.
7. Gruber R, Joober R, Grizenko N, Leventhal BL, Cook EH. jr., Stein MA. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19 (3): 233-239.
8. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 2004; 14 (4): 564-574.
9. Joober R, Grizenko N, Sengupta S et al. Dopamine transporter 30-UTR VNTR genotype and ADHD: a pharmaco- behavioural genetic study with methylphenidate. Neuropsychopharmacology 2007; 32 (6): 1370-1376. (Pubitemid 46788847)
10. Kereszturi E, Tarnok Z, Bognar E et al. Catechol-Omethyltransferase Val158-Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 2008; 147B (8): 1431-1435.
11. Kim JW, Biederman J, Arbeitman L, Fagerness J, Doyle AE, Petty C, Perlis RH, Purcell S, Smoller JW, Faraone SV, Sklar P. Investigation of variation in SNAP-25 and ADHD and relationship to co-morbid major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B (6): 781-790. (Pubitemid 47417208)
12. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham C, Shigawa S, Moyzis R, Vitiello B. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45 (11): 1314-1322.
13. McGough JJ, Barkley RA: Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161: 1948-1956. (Pubitemid 39441393)
14. Nobile M, Rusconi M, Bellina M, Marino C, Giorda R, Carlet O, Vanzin L, Molteni M, Battaglia M. COMT Val158-Met polymorphism and socioeconomic status interact to predict attention deficit/ hyperactivity problems in children aged 10-14. Eur Child Adolesc Psychiatry 2010; 19 (7): 549-557.
15. Polanczyk G, Zeni C, Genro JP et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention- deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64 (2): 218-224. (Pubitemid 46220779)
16. Polanczyk G, Faraone SV, Bau CH, Victor MM, Becker K, Pelz R, Buitelaar JK, Franke B, Kooij S, van der Meulen E, Cheon KA, Mick E, Purper-Ouakil D, Gorwood P, Stein MA, Cook EH Jr, Rohde LA. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet 2008; 147B (8): 1419-1424.
17. Ptáček R, Raboch J. Určení rozsahu souboru a power analýza v psychiatrickém výzkumu. Čes a slov Psychiat 2010; 106 (1): 33-41.
18. Purper-Ouakil D, Wohl M, Orejarena S, Cortese S, Boni C, Asch M, Mouren MC, Gorwood P. Pharmacogenetics of methylphenidate response in attention deficit/hype ractivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet 2008; 147B (8): 1425-1430.
19. Roman T, Szobot C, Martins S et al. Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics 2002; 12 (6): 497-499. (Pubitemid 34913533)
20. Roman T, Rohde LA, Hutz MH. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit- hyperactivity disorder. Am J Pharmacogenomics 2004; 4(2): 83-92. (Pubitemid 38560315)
21. Schmitz M, Denardin D, Silva TL, Pianca T, Roman T, Hutz MH, Faraone SV, Rohde LA. Association between alpha-2a-adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry 2006; 60 (10): 1028-1033. (Pubitemid 44647211)
22. Seeger G, Schloss P, Schmidt MH. Marker gene polymorphisms in hyperkinetic disorder: predictors of clinical response to treatment with methylphenidate? Neurosci Lett 2001; 313 (1-2): 45-48.
23. Stein MA, Waldman ID, Sarampote CS et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005; 30 (7): 1374-1382.
24. Tharoor H, Lobos EA, Todd RD et al. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147B (4): 527-530. (Pubitemid 351830816)
25. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38 (12): 1474-1477.
26. Yang L, Wang YF, Li J et al. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 2004; 43 (9): 1154-1158. (Pubitemid 39096873)
27. Zeni CP, Guimaraes AP, Polanczyk GV et al: No signifiant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144 (3): 391-394.